Free tool
FAERS Monitor: Nereus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220152 or its brand name (Nereus, Tradipitant). Reports on generic versions are filed under their own applications.
Reports
2
Serious
2
100% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- renal tubular necrosis2
- blood creatinine increased1
- protein total increased1
- sepsis1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| protein total increased | 1 | 3951.6 | 987.7 | 987 |
| renal tubular necrosis | 2 | 2146.0 | 2103.9 | 2,412 |
| blood creatinine increased | 1 | 161.1 | 40.3 | 39 |
| sepsis | 1 | 94.3 | 23.6 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.